Vir Biotechnology Inc [VIR] stock prices are up 0.27% to $7.40 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VIR shares have gain 3.42% over the last week, with a monthly amount drifted -0.54%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on January 29, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $9 from $23. Previously, BofA Securities downgraded its rating to Neutral on September 08, 2023, and dropped its price target to $14. On March 06, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $34 on the stock. Goldman upgraded its rating to a Buy and increased its price target to $53 on February 21, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $30 on January 27, 2023. SVB Leerink started tracking with a Outperform rating for this stock on September 14, 2022, and assigned it a price target of $40. In a note dated September 09, 2022, Morgan Stanley initiated an Underweight rating and provided a target price of $15 on this stock.
The stock price of Vir Biotechnology Inc [VIR] has been fluctuating between $6.56 and $13.09 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $7.40 at the most recent close of the market. An investor can expect a potential return of 278.38% based on the average VIR price forecast.
Analyzing the VIR fundamentals
The Vir Biotechnology Inc [NASDAQ:VIR] reported sales of 78.62M for trailing twelve months, representing a drop of -9.81%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -6.58%, Pretax Profit Margin comes in at -6.86%, and Net Profit Margin reading is -6.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.37 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.24 points at the first support level, and at 7.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.50, and for the 2nd resistance point, it is at 7.59.
Ratios To Look Out For
It’s worth pointing out that Vir Biotechnology Inc [NASDAQ:VIR]’s Current Ratio is 8.94. As well, the Quick Ratio is 8.94, while the Cash Ratio is 1.44. Considering the valuation of this stock, the price to sales ratio is 12.96, the price to book ratio is 0.82.
Transactions by insiders
Recent insider trading involved de Verneuil Vanina, EVP and General Counsel, that happened on Dec 02 ’24 when 76.0 shares were sold. Officer, VANINA ALEXANDRA HUARD DE VERN completed a deal on Dec 02 ’24 to buy 76.0 shares. Meanwhile, EVP and General Counsel de Verneuil Vanina sold 4397.0 shares on Nov 06 ’24.
